The value of popular weight loss drugs — such as Novo Nordisk's (NVO) Ozempic and Wegovy — could reach an expected total addressable market (TAM) of $100 billion by 2030, according to a Goldman Sachs report. Major retailers and food brands have communicated concerns about these drugs being a gut punch to snack and general food sales. Goldman Sachs Research Analyst Jason English explains why that may not exactly be the case for junk food sales figures and how consumers are reshaping their spending habits amid the weight loss trend. "Where we saw some surprises, it wasn't junk food being disproportionately damaged, instead it was more healthy food," English tells Yahoo Finance. "Weight management bars saw the largest drop in demand with its cohort, so did salad dressings, meanwhile confections were relatively unchanged, salty snacks down, but really down no worse than most food demand was down." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.